Preclinical Efficacy of Novel Dual PI3K/mTOR Inhibitor CMG002 As Potential Anti-Hepatocellular Carcinoma Agent

被引：0
|
作者：
Kim, Mi Na [1 ]
Lee, Seung Min [2 ]
Hwang, Seong-Gyu [3 ]
机构：
[1] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Pochon, South Korea
[2] CHA Univ, CHA Bundang Med Ctr, Inst Clin Res, Pochon, South Korea
[3] Cha Bundang Med Ctr, Seongnam, South Korea
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2233
引用
收藏
页码：1266A / 1266A
页数：1
相关论文
共 50 条
  • [41] Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
    Jin, Ning
    Jiang, Tianyun
    Rosen, David M.
    Nelkin, Barry D.
    Ball, Douglas W.
    CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6482 - 6489
  • [42] Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
    Mallon, Robert
    Feldberg, Larry R.
    Lucas, Judy
    Chaudhary, Inder
    Dehnhardt, Christoph
    Delos Santos, Efren
    Chen, Zecheng
    dos Santos, Osvaldo
    Ayral-Kaloustian, Semiramis
    Venkatesan, Aranapakam
    Hollander, Irwin
    CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3193 - 3203
  • [43] The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
    Shi, Fei
    Zhang, Jinying
    Liu, Hongyu
    Wu, Liangliang
    Jiang, Hongyu
    Wu, Qiyan
    Liu, Tianyi
    Lou, Meiqing
    Wu, Hao
    ONCOTARGET, 2018, 9 (01) : 706 - 717
  • [44] A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma
    Li, Yunyun
    Zhang, Zhongzu
    Zhang, Xiaojing
    Lin, Ying
    Luo, Tangshu
    Xiao, Zhenghua
    Zhou, Qin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (02): : 719 - 731
  • [45] Preclinical efficacy of GNE-317, a dual PI3K/mTOR inhibitor, with or without bevacizumab in EGFR and/or PTEN-mutated glioblastoma multiforme
    Sio, Terence T.
    Pokorny, Jenny L.
    Mladek, Ann C.
    Carlson, Brett L.
    Schroeder, Mark A.
    Iyekegbe, Dennis O.
    Bakken, Katrina
    Salphati, Laurent
    Phillips, Heidi
    Sarkaria, Jann N.
    CANCER RESEARCH, 2014, 74 (19)
  • [46] Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors
    Wu, Ting-Ting
    Guo, Qing-Qing
    Chen, Zi-Li
    Wang, Li-Li
    Du, Yao
    Chen, Rui
    Mao, Yuan-Hu
    Yang, Sheng-Gang
    Huang, Jing
    Wang, Jian-Ta
    Wang, Ling
    Tang, Lei
    Zhang, Ji-Quan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 204
  • [47] Discovery of the potent PI3K/mTOR dual inhibitor PF-04979064
    Cheng, Hengmiao
    Bagrodia, Shubha
    Bailey, Simon
    Baxi, Sangita M.
    Goulet, Lance
    Guo, Lisa
    Hoffman, Jacqui
    Johnson, Ted O.
    Johnson, Ted W.
    Li, Chunze
    Li, John
    Liu, Kevin
    Liu, Zhengyu
    Marx, Matthew A.
    Paderes, Gigi
    Sun, Shaoxian
    Walls, Marlena
    Wells, Peter A.
    Yang, Anle
    Yin, Min-Jean
    Zhu, Jingjiang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [48] Preclinical studies of the PI3K/mTOR dual inhibitors in endometrial cancer cell lines
    Yuan, Jing
    Garza, Scott J.
    Cao, Joan
    Fisher, Timothy S.
    Lee, Nathan V.
    Eisele, Koleen
    Pasis, Angela
    Hook, Kenneth
    Christensen, James G.
    Kan, Julie L.
    CANCER RESEARCH, 2012, 72
  • [49] The Role of PI3K/mTOR Inhibition in Combination with Sorafenib in Hepatocellular Carcinoma Treatment
    Gedaly, Roberto
    Angulo, Paul
    Chen, Changguo
    Creasy, Kate Townsend
    Spear, Brett T.
    Hundley, Jonathan
    Daily, Michael F.
    Shah, Malay
    Evers, B. Mark
    ANTICANCER RESEARCH, 2012, 32 (07) : 2531 - 2536
  • [50] Radiosensitization by the Dual PI3K/mTOR inhibitor NVP-BEZ235
    Cerniglia, George J.
    Karar, Jayashree
    Koumenis, Constantinos
    Maity, Amit
    CANCER RESEARCH, 2012, 72
12345